相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cyclins and cyclin-dependent kinases: from biology to tumorigenesis and therapeutic opportunities
Mitra Zabihi et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)
Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor-positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities
Maxwell R. Lloyd et al.
CLINICAL CANCER RESEARCH (2022)
Cell cycle control in cancer
Helen K. Matthews et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2022)
CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities
Erik S. Knudsen et al.
CELL REPORTS (2022)
Origin of Cancer: Cell work is the Key to Understanding Cancer Initiation and Progression
Rainer G. Hanselmann et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2022)
From cyclins to CDKIs: Cell cycle regulation of skeletal muscle stem cell quiescence and activation
Despoina Mademtzoglou et al.
EXPERIMENTAL CELL RESEARCH (2022)
Phase I trial of ribociclib with platinum chemotherapy in ovarian cancer
Lan G. Coffman et al.
JCI INSIGHT (2022)
Additive Effect of CD73 Inhibitor in Colorectal Cancer Treatment With CDK4/6 Inhibitor Through Regulation of PD-L1
Ji-Yoon Noh et al.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY (2022)
DNA damage checkpoint execution and the rules of its disengagement
Candice Qiu Xia Yam et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2022)
Differential Regulation of Cancer Progression by CDK4/6 Plays a Central Role in DNA Replication and Repair Pathways
Meiou Dai et al.
CANCER RESEARCH (2021)
Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial
Amita Patnaik et al.
CLINICAL CANCER RESEARCH (2021)
Regulatory mechanism of cyclins and cyclin-dependent kinases in post-mitotic neuronal cell division
Rohan Gupta et al.
LIFE SCIENCES (2021)
CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory
Emily J. Lelliott et al.
CANCER DISCOVERY (2021)
Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma
Emily J. Lelliott et al.
FRONTIERS IN IMMUNOLOGY (2021)
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
D. J. Slamon et al.
ANNALS OF ONCOLOGY (2021)
Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer
Yuan Yuan et al.
EUROPEAN JOURNAL OF CANCER (2021)
CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy
Valerio Nardone et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
The Influence of Cell Cycle Regulation on Chemotherapy
Ying Sun et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Targeting cyclin-dependent kinase 4/6 as a therapeutic approach for mucosal melanoma
Chao-ji Shi et al.
MELANOMA RESEARCH (2021)
Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naive Metastatic Breast Cancer
Richard S. Finn et al.
CLINICAL CANCER RESEARCH (2020)
Alterations of cell cycle genes in cancer: unmasking the role of cancer stem cells
Hasan Onur Caglar et al.
MOLECULAR BIOLOGY REPORTS (2020)
Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition
Monica Alvarez-Fernandez et al.
CANCER CELL (2020)
Structural interconversions of the anaphase-promoting complex/cyclosome (APC/C) regulate cell cycle transitions
David Barford
CURRENT OPINION IN STRUCTURAL BIOLOGY (2020)
CDK4/6 inhibitors in P16/HPV16-negative squamous cell carcinoma of the head and neck
Camelia Billard-Sandu et al.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY (2020)
The role of CDK6 in cancer
Sofie Nebenfuehr et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
Seth A. Wander et al.
CANCER DISCOVERY (2020)
Novel Therapeutic Strategies for CDK4/6 Inhibitors in Metastatic Castrate-Resistant Prostate Cancer
Adam M. Kase et al.
ONCOTARGETS AND THERAPY (2020)
CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy
Anne Y. Lai et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Combined CDK4/6 and PD-1 Inhibition in Refractory SMARCA4-Deficient Small-Cell Carcinoma of the Ovary, Hypercalcemic Type
Elizabeth K. Lee et al.
JCO PRECISION ONCOLOGY (2020)
CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner
Qian-Feng Zhang et al.
THERANOSTICS (2020)
Mitotic Chromosome Mechanics: How Cells Segregate Their Genome
Paul Batty et al.
TRENDS IN CELL BIOLOGY (2019)
Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma
Jiayi Yu et al.
CLINICAL CANCER RESEARCH (2019)
Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment
Jessica L. F. Teh et al.
CLINICAL CANCER RESEARCH (2019)
Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2019)
Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy
Valeria Mollica Poeta et al.
FRONTIERS IN IMMUNOLOGY (2019)
To Cycle or Fight-CDK4/6 Inhibitors at the Crossroads of Anticancer Immunity
Malaka Ameratunga et al.
CLINICAL CANCER RESEARCH (2019)
Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance
Jinfang Zhang et al.
NATURE (2018)
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Jiehui Deng et al.
CANCER DISCOVERY (2018)
Targeting Cyclin D-CDK4/6 Sensitizes Immune-Refractory Cancer by Blocking the SCP3-NANOG Axis
Se Jin Oh et al.
CANCER RESEARCH (2018)
Multiple functions of p27 in cell cycle, apoptosis, epigenetic modification and transcriptional regulation for the control of cell growth: A double-edged sword protein
Maryam Abbastabar et al.
DNA REPAIR (2018)
Beyond the Cell Cycle: Enhancing the Immune Surveillance of Tumors Via CDK4/6 Inhibition
Andrea C. Chaikovsky et al.
MOLECULAR CANCER RESEARCH (2018)
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade
David A. Schaer et al.
CELL REPORTS (2018)
CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest
Shom Goel et al.
TRENDS IN CELL BIOLOGY (2018)
Simulation of Stimulation: Cytokine Dosage and Cell Cycle Crosstalk Driving Timing-Dependent T Cell Differentiation
Matteo Barberis et al.
FRONTIERS IN PHYSIOLOGY (2018)
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W. Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
CDK4/6 inhibition triggers anti-tumour immunity
Shom Goel et al.
NATURE (2017)
MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer
A. Bouillez et al.
ONCOGENE (2017)
Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations
Laura M. Spring et al.
ONCOLOGIST (2017)
Inhibitors of cyclin-dependent kinases as cancer therapeutics
Steven R. Whittaker et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Genome organization during the cell cycle: unity in division
Rosela Golloshi et al.
WILEY INTERDISCIPLINARY REVIEWS-SYSTEMS BIOLOGY AND MEDICINE (2017)
Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer
Zhi Ling Teo et al.
CANCER RESEARCH (2017)
Cell-Cycle Proteins Control Production of Neutrophil Extracellular Traps
Borko Amulic et al.
DEVELOPMENTAL CELL (2017)
CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
Elizabeth I. Buchbinder et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
Cyclin D1, cancer progression, and opportunities in cancer treatment
Shuo Qie et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2016)
Treating cancer with selective CDK4/6 inhibitors
Ben O'Leary et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer: Past, Present, and Future
Adam J. DiPippo et al.
PHARMACOTHERAPY (2016)
Cyclin-Dependent Kinases as Coregulators of Inflammatory Gene Expression
M. Lienhard Schmitz et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
Amita Patnaik et al.
CANCER DISCOVERY (2016)
The history and future of targeting cyclin-dependent kinases in cancer therapy
Uzma Asghar et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Cdks, cyclins and CKIs: roles beyond cell cycle regulation
Shuhui Lim et al.
DEVELOPMENT (2013)
Emerging roles of RB family: New defense mechanisms against tumor progression
Paola Indovina et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2013)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
A Requirement for Cyclin-Dependent Kinase 6 in Thymocyte Development and Tumorigenesis
Miaofen G. Hu et al.
CANCER RESEARCH (2009)
Cell cycle, CDKs and cancer: a changing paradigm
Marcos Malumbres et al.
NATURE REVIEWS CANCER (2009)
The Immunological Genome Project: networks of gene expression in immune cells
Tracy S. P. Heng et al.
NATURE IMMUNOLOGY (2008)
Cellular mechanisms of tumour suppression by the retinoblastoma gene
Deborah L. Burkhart et al.
NATURE REVIEWS CANCER (2008)
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Wen Xue et al.
NATURE (2007)
Cyclin-dependent kinase pathways as targets for cancer treatment
GI Shapiro
JOURNAL OF CLINICAL ONCOLOGY (2006)
Mammalian cells cycle without the D-type cyclin-elependent kinases Cdk4 and Cdk6
M Malumbres et al.
CELL (2004)
Cyclin dependent kinases and cell cycle control
PM Nurse
BIOSCIENCE REPORTS (2002)
RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer
FJ Kaye
ONCOGENE (2002)
Oncogenic ras and p53 cooperate to induce cellular senescence
G Ferbeyre et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Cell-cycle regulation in immunity, tolerance and autoimmunity
D Balomenos et al.
IMMUNOLOGY TODAY (2000)
分享论文
